β
Outcome MeasureOther

VAS

Visual Analogue Scale

3 Papers in Blossom

Outcome Data Across Studies

Reported results for VAS across 3 studies with quantitative data.

Outcome data across 5 study arm–timepoint observations
SD
The hidden therapist: evidence for a central role of music in psychedelic therapy
2018Secondary
Psilocybin(experimental)019———
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)014———
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)01484.421.5—
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)01424.725.8—
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
2026Secondary
LSD microdose(experimental)019———

Papers Using VAS

Open Accessindividual

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

This open-label trial (n=19) found that repeated microdosed LSD (8 to 20 μg) was associated with short-term improvements in daily mood, but not same-day changes in self-reported depression, in people with major depressive disorder. It also provided pharmacokinetic data for sublingual LSD and found no evidence of tolerance or sensitisation across the 8-week dosing regimen.

Published
Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R., Forsyth, A., Jeong, S. H., Evans, W., Alshakhouri, M., Murphy, R. J., Reynolds, L., Hoeh, N., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
Journal
Neuropsychopharmacology
Authors
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.
Open Accessindividual

The hidden therapist: evidence for a central role of music in psychedelic therapy

This open-label qualitative interview study (n=19) assessed the role of music during psychedelic therapy with psilocybin (25mg) for treatment-resistant depression (TRD). It identified several ways in which music influenced their experience, most frequently related to the intensification of emotions and mental imagery, and the music appeared to be a significant source of guidance, creating a sense of grounding, as well as a sense of carrying the listener into different psychological places.

Published
Journal
Psychopharmacology
Authors
Kaelen, M., Giribaldi, B., Raine, J., Evans, J., Timmermann, C., Roseman, L., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., Rodrigues, N. B.

Quick Facts

Full Name
Visual Analogue Scale
Domain
Other
Papers Indexed
3
Score Range
0–100
Interpretation
Lower = better
Unit
mm
All Measures